- Home
- RLMD vs GPRK Comparison
RLMD vs GPRK Comparison
Compare RLMD & GPRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLMD | GPRK |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | United States | Colombia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.1M | 629.3M |
| IPO Year | 2012 | 2009 |
Fundamental Metrics
Financial Performance| Metric | RLMD | GPRK |
|---|---|---|
| Price | $6.93 | $11.35 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $12.40 | $8.50 |
| AVG Volume (30 Days) | ★ 869.6K | 524.4K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.26% |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $39.45 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.70 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.52 | $5.75 |
| 52 Week High | $8.00 | $10.51 |
Technical Indicators
Market Signals| Indicator | RLMD | GPRK |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 69.96 |
| Support Level | $6.81 | $7.87 |
| Resistance Level | $7.46 | N/A |
| Average True Range (ATR) | 0.42 | 0.45 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 50.17 | 98.46 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
About GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.